Dyadic International’s (DYAI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Dyadic International (NASDAQ:DYAI) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $6.00 price target on the biotechnology company’s stock.

Dyadic International Trading Down 0.9 %

NASDAQ:DYAI opened at $1.13 on Thursday. The company has a quick ratio of 5.39, a current ratio of 5.15 and a debt-to-equity ratio of 1.54. The business’s 50 day moving average is $1.12 and its two-hundred day moving average is $1.42. Dyadic International has a 52 week low of $0.93 and a 52 week high of $2.67. The company has a market cap of $33.43 million, a PE ratio of -4.91 and a beta of 0.72.

Dyadic International (NASDAQ:DYAI) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. The company had revenue of $1.96 million for the quarter, compared to the consensus estimate of $1.05 million. During the same quarter last year, the business posted ($0.06) EPS. On average, analysts predict that Dyadic International will post -0.28 EPS for the current year.

Institutional Trading of Dyadic International

A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. lifted its stake in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 847,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the quarter. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 as of its most recent filing with the Securities and Exchange Commission. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.